Allelic Variants of Drug Metabolizing Enzymes as Risk Factors in Psoriasis
- 1 May 2003
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (5) , 765-770
- https://doi.org/10.1046/j.1523-1747.2003.12124.x
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- The Genetics of Psoriasis 2001Archives of Dermatology, 2001
- The genetics of psoriasis: a complex disorder of the skin and immune systemHuman Molecular Genetics, 1998
- Genetics of Psoriasis: Paternal Inheritance and a Locus on Chromosome 6pJournal of Investigative Dermatology, 1998
- Alteration of a model antigen by Au(III) leads to T cell sensitization to cryptic peptidesEuropean Journal of Immunology, 1996
- CD8+ T cells in psoriatic lesions preferentially use T-cell receptor V beta 3 and/or V beta 13.1 genes.Proceedings of the National Academy of Sciences, 1994
- Loss of Heterozygosity at the NAD(P)H:Quinone Oxidoreductase Locus Associated with Increased Resistance against Mitomycin C in a Human Bladder Carcinoma Cell LineBiological Chemistry Hoppe-Seyler, 1994
- β-Adrenergic blocking drugs and psoriasis: The role of an immunologic mechanismJournal of the American Academy of Dermatology, 1993
- Drugs in exacerbation of psoriasisJournal of the American Academy of Dermatology, 1986
- Aryl Hydrocarbon Hydroxylase, Epoxide Hydrolase, and Benzo[a]pyrene Metabolism in Human Epidermis: Comparative Studies in Normal Subjects and Patients with PsoriasisJournal of Investigative Dermatology, 1984
- ACTIVITY OF ARYL HYDROCARBON HYDROXYLASE IN PSORIATIC SKINThe Lancet, 1979